Vise Technologies Inc. purchased a new position in shares of Kenvue Inc. (NYSE:KVUE – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 30,353 shares of the company’s stock, valued at approximately $580,000.
A number of other large investors also recently modified their holdings of KVUE. BlackRock Inc. acquired a new stake in Kenvue during the 2nd quarter worth approximately $2,882,279,000. Norges Bank acquired a new position in Kenvue during the fourth quarter valued at approximately $756,862,000. Independent Franchise Partners LLP grew its stake in Kenvue by 56.3% during the fourth quarter. Independent Franchise Partners LLP now owns 48,146,476 shares of the company’s stock worth $830,527,000 after buying an additional 17,343,785 shares during the period. Sculptor Capital LP grew its stake in Kenvue by 1,023.5% during the fourth quarter. Sculptor Capital LP now owns 12,886,328 shares of the company’s stock worth $222,289,000 after buying an additional 11,739,328 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Kenvue in the second quarter worth $192,080,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several equities analysts recently weighed in on the stock. Weiss Ratings upgraded shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. Zacks Research downgraded Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Barclays raised their price objective on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 21st. Wall Street Zen lowered Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, UBS Group dropped their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a report on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the company’s stock. According to MarketBeat, Kenvue currently has an average rating of “Hold” and an average price target of $19.27.
Kenvue Stock Performance
Kenvue stock opened at $19.41 on Tuesday. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $21.63. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.01 and a quick ratio of 0.71. The company has a market capitalization of $37.27 billion, a price-to-earnings ratio of 22.30, a price-to-earnings-growth ratio of 1.36 and a beta of 0.47. The firm’s fifty day moving average price is $19.08 and its 200 day moving average price is $18.21.
Kenvue (NYSE:KVUE – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The firm had revenue of $3.96 billion for the quarter, compared to analyst estimates of $3.97 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.29 earnings per share. On average, research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.
Kenvue Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th will be given a dividend of $0.21 per share. The ex-dividend date of this dividend is Wednesday, August 12th. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.84 annualized dividend and a yield of 4.3%. Kenvue’s payout ratio is presently 96.55%.
Kenvue Company Profile
Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.
The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.
Featured Articles
- Five stocks we like better than Kenvue
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.
